Plecanatide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Plecanatide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
13
Registered trials
16
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Plecanatide can convert its Synthetic peptide, Cyclic Peptide profile and GC-C biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Plecanatide (query alias: plecanatide) |
|---|---|
| Modality / target | Synthetic peptide, Cyclic Peptide; GC-C; GC-C agonists |
| Highest global status | Approved |
| Originator | Synergy Pharmaceuticals LLC |
| Active developers | Cipher Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc., Bausch Health Cos., Inc. |
The MCP disease footprint includes Irritable Bowel Syndrome, Irritable bowel syndrome with constipation, Chronic idiopathic constipation. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05151328 | Phase 3 | Completed | 648 | Number of Durable Overall CSBM Responders, Mean Replacement Approach |
| CTRI/2022/03/040704 | Phase 3 | Completed | 210 | Not disclosed |
| NCT03596905 | Phase 2 | Completed | 218 | Change From Baseline in Weekly Spontaneous Bowel Movement (SBM) Frequency Over the 4 Week Treatment Period Compared to Placebo and Across Treatment Groups |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
The Effectiveness of Plecanatide for Treating Constipation and Bloating in Patients Aged 18 to 40 Years With Irritable Bowel Syndrome: Utilization of a New Composite Trisymptom Endpoint
Phase 3; n=605; evaluation: Positive. Reported fields: Bloating = Plecanatide/placebo baseline mean symptom scores were 6.2/6.4 for abdominal pain and 6.4/6.6 for bloating; both had a mean of 0.2 CSBMs/week. ; Bloating = Plecanatide/placebo baseline mean symptom scores were 6.2/6.4 for abdominal pain and 6.4/6.6 for bloating; both had a mean of 0.2 CSBMs/week.
Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo‐controlled trials in adults with severe constipation
Phase 3; n=4815; evaluation: Positive. Reported fields: ORR(IBS-C) = 31.0 % ; ORR(IBS-C) = 33.0 % ; ORR(IBS-C) = 19.0 %
EARLY RESPONSE TO PLECANATIDE PREDICTS OVERALLAND SUSTAINED EFFICACY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: ORs during Weeks 1-12 = 26.7 % ; ORs during Weeks 1-12 = 25.6 % ; ORs during Weeks 1-12 = 16.0 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Plecanatide addresses Irritable Bowel Syndrome, Irritable bowel syndrome with constipation, Chronic idiopathic constipation. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide, Cyclic Peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc. | Approved | US$200.0M stated total | |
| 2018-08-07 | Luoixn partners with Synergy Pharmaceuticals to develop and market Trulance for the treatment of CIC and IBS-C in mainland China, Hong Kong, and Macau. | Approved | US$12.0M upfront; US$56.0M milestones; US$68.0M stated total |
| 2018-02-26 | Bausch Health to Acquire Certain Assets of Synergy Pharmaceuticals Inc. | Approved | US$5.0M upfront |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Application of plecanatide in preparation of weight-losing and lipid-lowering medicines or medicines with lipase activity inhibition effect”. The milestone feed surfaced a patent-application signal described as “Method for synthesizing plecanatide through natural chemical ligation method”. The milestone feed surfaced a patent-application signal described as “Method for purifying plecanatide”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
